Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)

Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2017, Vol.47 (1), p.102-106
Main Authors: Popova, E. V., Boiko, A. N., Boiko, O. V.
Format: Article
Language:English
Subjects:
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Comparative studies
Multiple sclerosis
Neurobiology
Neurosciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line agents are used in this situation, which on the territories of the Russian Federation include fingolimod. Experience in the use of fingolimod in routine neurological practice was obtained by performing the postmarketing GIMN trial.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-016-0370-2